Latest news
Developments in research to improve the treatment of patients with cancer.
Read the latest news
New study using Hartwig Medical Foundation data maps how breast cancer’s genetic makeup shifts when it spreads
Analysis of nearly 1,300 tumor genomes across ten genomic subtypes points to candidate drug targets and biomarkers for metastatic breast …
Hartwig receives CE certification for OncoAct, the first complete IVDR-certified whole-genome cancer diagnostics solution
We are proud to announce that Hartwig Medical Foundation has received CE certification under the European In Vitro Diagnostic Regulation …
Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment
Researchers from Vall d’Hebron Institute of Oncology identify genomic signals predicting non-response to cancer therapies in collaboration with Hartwig Medical …
Read the latest blogs
Expansion of the Hartwig Client Portal: registration becomes easier, safer, and smarter
The expansion of the Hartwig Client Portal marks another important step in further digitizing the collaboration between Hartwig Medical Foundation …
Read more
DataNexus connects clinical and genomic data
DataNexus is a project initiated by the Netherlands Cancer Institute–Antoni van Leeuwenhoek (NKIAvL) to improve data availability by integrating clinical …
Read more
How do you analyze 8,000 Tumor/Normal genomes in under two months?
It has been a long time coming: Hartwig Medical Foundation has transitioned to the GRCh38 (hg38) reference genome! For years, …
Read more
Cancer is caused by DNA mutations. There are an increasing number of drugs available that act on specific errors in the DNA of an individual patient’s tumor. A drug that doesn’t fit, like a key in a lock, will not work, while the risk of side effects remains.